Experimental method for verifying bumetanib capable of improving cognitive impairment of schizophrenia
The invention provides an experimental method for verifying that bumetanib can improve cognitive impairment of schizophrenia. The experimental method is characterized by comprising the following steps: step 1, preparing rats of a schizophrenia model group and rats of a control group; 2, verifying th...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
28.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The invention provides an experimental method for verifying that bumetanib can improve cognitive impairment of schizophrenia. The experimental method is characterized by comprising the following steps: step 1, preparing rats of a schizophrenia model group and rats of a control group; 2, verifying that the schizophrenia model group rats have NKCC1/KCC2 expression imbalance through an immunoblotting experiment; and 3, verifying that the bumetanib can improve the cognitive impairment of the schizophrenia model group rats. Results of multiple experiments show that the schizophrenia model group rats have significant NKCC1/KCC2 imbalance, while the NKCC1/KCC2 system regulation drug bumetanib can significantly improve cognitive impairment of the schizophrenia model group rats, and the bumetanib has the advantages of short onset period and efficient and stable improvement effect, thereby proving the therapeutic value of bumetanib in schizophrenia cognitive impairment.
本发明提供一种验证布美他尼能改善精神分裂症认知损伤的实验方法,其特征在于包括以下步骤:步骤一:制备 |
---|---|
AbstractList | The invention provides an experimental method for verifying that bumetanib can improve cognitive impairment of schizophrenia. The experimental method is characterized by comprising the following steps: step 1, preparing rats of a schizophrenia model group and rats of a control group; 2, verifying that the schizophrenia model group rats have NKCC1/KCC2 expression imbalance through an immunoblotting experiment; and 3, verifying that the bumetanib can improve the cognitive impairment of the schizophrenia model group rats. Results of multiple experiments show that the schizophrenia model group rats have significant NKCC1/KCC2 imbalance, while the NKCC1/KCC2 system regulation drug bumetanib can significantly improve cognitive impairment of the schizophrenia model group rats, and the bumetanib has the advantages of short onset period and efficient and stable improvement effect, thereby proving the therapeutic value of bumetanib in schizophrenia cognitive impairment.
本发明提供一种验证布美他尼能改善精神分裂症认知损伤的实验方法,其特征在于包括以下步骤:步骤一:制备 |
Author | LYU LUXIAN SU XI KANG NING LIU QING CHEN YI YANG YONGFENG CHAI RUI LI WENQIANG |
Author_xml | – fullname: LIU QING – fullname: CHEN YI – fullname: LI WENQIANG – fullname: YANG YONGFENG – fullname: SU XI – fullname: CHAI RUI – fullname: LYU LUXIAN – fullname: KANG NING |
BookMark | eNqNjD0KwkAQRrfQwr87jAcQDIKSUkLEyso-TNbZZCCZWTZrUE9vFjyA1Qfve7ylmYkKLYwrX54C9yQRO-gptvoApwHGibo3SwP1c8IoXINFj3VHoA6490HHdFtthCOPlBhySKlkDLblj_o2kDCuzdxhN9DmtyuzvZT34rojrxUNHi0Jxaq4Zdlxn-WnPD8f_nG-W1lCgw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences Forestry Agriculture |
DocumentTitleAlternate | 一种验证布美他尼能改善精神分裂症认知损伤的实验方法 |
ExternalDocumentID | CN116019799A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CN116019799A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:23:29 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Chinese English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CN116019799A3 |
Notes | Application Number: CN202211401957 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230428&DB=EPODOC&CC=CN&NR=116019799A |
ParticipantIDs | epo_espacenet_CN116019799A |
PublicationCentury | 2000 |
PublicationDate | 20230428 |
PublicationDateYYYYMMDD | 2023-04-28 |
PublicationDate_xml | – month: 04 year: 2023 text: 20230428 day: 28 |
PublicationDecade | 2020 |
PublicationYear | 2023 |
RelatedCompanies | HENAN PSYCHIATRIC HOSPITAL (THE SECOND AFFILIATED HOSPITAL OF XINXIANG MEDICAL COLLEGE) |
RelatedCompanies_xml | – name: HENAN PSYCHIATRIC HOSPITAL (THE SECOND AFFILIATED HOSPITAL OF XINXIANG MEDICAL COLLEGE) |
Score | 3.5992703 |
Snippet | The invention provides an experimental method for verifying that bumetanib can improve cognitive impairment of schizophrenia. The experimental method is... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | AGRICULTURE ANIMAL HUSBANDRY CARE OF BIRDS, FISHES, INSECTS FISHING FORESTRY HUMAN NECESSITIES HUNTING HYGIENE MEDICAL OR VETERINARY SCIENCE NEW BREEDS OF ANIMALS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TRAPPING |
Title | Experimental method for verifying bumetanib capable of improving cognitive impairment of schizophrenia |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230428&DB=EPODOC&locale=&CC=CN&NR=116019799A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD7MKV6edCo6L0SQvhV7Sbf2ociWtgzBbsiUvY2mzbQi21grgr_ek9hdXvQtJOFA0p6c-3cAbs3EMLhte3rbyTKduoLqXuJIN4fj0XZqWulEoX3Grd4zfRg5oxq8L2thFE7olwJHRI5Kkd9L9V7P106sQOVWFnc8x6nZfTT0A62yjqWH03K1oOuHg37QZxpjPou1-Mk3TbQ8ZAirswXbUo2WOPvhS1dWpcw3RUp0CDsDpDYtj6D2_daAg87rooLBEA3YY8s-bA3Yld0zq-FjFQnHYcWUxTFMwg2UfvLbEpqgLkrwL81VGRPh-AKhFphzkqJw5B-CzCYkX_oTyCqHSM4l-UKSkjuKzYy8E7iJwiHr6XiS8eraxixeH9o-hfp0NhVnQDI0skTLoBnyKhV25rZd7iWtRIF2UtM4h-bfdJr_LV7AvvwEMtZiuZdQLxef4gpFdsmv1V3_AKdVnHk |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8gGtEnRY3iV03M3hY31rHtYTHYQVBhEIOGN7JuRWcMEJgx8a_3WsfHi7413XJJu12vv_v4HcC1GRkGtyxPd-wk0akrqO5FtnRz2B51YrMajxTbZ1hrPdOHgT0owPuiFkbxhH4pckTUqBj1PVPn9XTlxApUbuX8hqc4Nblt9v1Ay9Gx9HBWXS248xu9btBlGmM-C7XwyTdNRB4yhFXfgE0HIaGCSi93siplum5Smnuw1UNp42wfCt9vZditv85yGgxRhhJb9GErw7bsnpkPO3kkHIe5Us4PYNRYY-knvy2hCd5FCf6lqSpjIhxPILwFppzEaBz5hyCTEUkX_gSyzCGSc1E6k6LkG_P1jLxDuGo2-qyl40qGy20bsnC1aOsIiuPJWBwDSRBkiZpBE9RVKqzEdVzuRbVIkXZS0ziByt9yKv89vIRSq99pD9v34eMp7MjPIeMuVfcMitnsU5yj-c74hdr3Hx4Zn2M |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Experimental+method+for+verifying+bumetanib+capable+of+improving+cognitive+impairment+of+schizophrenia&rft.inventor=LIU+QING&rft.inventor=CHEN+YI&rft.inventor=LI+WENQIANG&rft.inventor=YANG+YONGFENG&rft.inventor=SU+XI&rft.inventor=CHAI+RUI&rft.inventor=LYU+LUXIAN&rft.inventor=KANG+NING&rft.date=2023-04-28&rft.externalDBID=A&rft.externalDocID=CN116019799A |